Utility of multiparametric magnetic resonance imaging in the risk stratification of men with Grade Group 1 prostate cancer on active surveillance-Reference-Cited by-同舟云学术

Utility of multiparametric magnetic resonance imaging in the risk stratification of men with Grade Group 1 prostate cancer on active surveillance

Published:2020-03-02 Issue:6 Volume:125 Page:861-866
ISSN:1464-4096
Container-title:BJU International
language:en
Short-container-title:BJU Int

Author:

Mamawala Mufaddal K.¹^ORCID,Meyer Alexa R.¹,Landis Patricia K.¹,Macura Katarzyna J.¹,Epstein Jonathan I.¹^ORCID,Partin Alan W.¹,Carter Ballentine H.¹,Gorin Michael A.¹^ORCID

Affiliation:

1. The James Buchanan Brady Urological Institute; Johns Hopkins Medical Institutions; Baltimore MD USA

Publisher

Wiley

Subject

Urology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bju.15033/fullpdf

Reference34 articles.

1. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up;Schroder;Lancet,2014

2. Contemporary use of initial active surveillance among men in Michigan with low-risk prostate cancer;Womble;Eur Urol,2015

3. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer;Klotz;J Clin Oncol,2015

4. Intermediate and longer-term outcomes from a prospective active-surveillance program for favorable-risk prostate cancer;Tosoian;J Clin Oncol,2015

5. Is delayed radical prostatectomy in men with low-risk screen-detected prostate cancer associated with a higher risk of unfavorable outcomes?;Bergh;Cancer,2010

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Gleason score 3+3=6 prostatic adenocarcinoma is not benign and the current debate is unhelpful to clinicians and patients;Pathology;2023-11

2. The role of PSMA PET/CT to predict upgrading in patients undergoing radical prostatectomy for ISUP grade group 1 prostate cancer;The Prostate;2023-09-03

3. Point-Counterpoint: Gleason Score 6/Grade Group 1 Prostate Cancer Should Be Renamed as “Non-cancer” to Improve Public Health: A Wrong Idea From a Pathologist’s Perspective;Journal of Urology;2023-07

4. Prediction of upgrade to clinically significant prostate cancer in patients under active surveillance: Performance of a fully automated AI‐algorithm for lesion detection and classification;The Prostate;2023-04-04

5. Prostate Adenocarcinoma Grade Group 1: Rationale for Retaining a Cancer Label in the 2022 World Health Organization Classification;European Urology;2023-04